205
Participants
Start Date
February 17, 2015
Primary Completion Date
February 1, 2016
Study Completion Date
April 12, 2016
VOX
100 mg tablet(s) administered orally once daily with food
SOF/VEL
400/100 mg FDC tablet administered orally once daily with food
RBV
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Cedars Sinai Medical Center, Los Angeles
Stanford University, Palo Alto
Huntington Memorial Hospital Liver Center, Pasadena
Medical Associates Research Group, Inc., San Diego
University of Colorado, Denver
Borland-Groover Clinic, Jacksonville
University of Miami, Miami
Orlando Immunology center, Orlando
South Florida Center of Gastroenterology, P.A., Wellington
Center for Hep C/Atlanta Medical Center, Atlanta
Gastrointestinal Specialists of Georgia, PC, Marietta
University of Chicago, Chicago
Indiana University, Indianapolis
Indianapolis Gastroenterology & Hepatology, Inc., Indianapolis
Beth Isreal Deconess Medical Center, Boston
Massachusetts General Hospital, Boston
Henry Ford Hospital and Health System, Detroit
ID Care, Hillsborough
Southwest Care Center, Santa Fe
North Shore/Long Island Jewish PRIME, Manhasset
Mount Sinai Beth Israel, New York
Cumberland Research Associates, LLC, Fayetteville
Digestive Health Specialists, PA, Winston-Salem
University of Pennsylvania Health Systems, Philadelphia
UPMC Center for Liver Diseases, Pittsburgh
Medical University of South Carolina, Charleston
Gastro One, Germantown
Nashville Gastrointestinal Specialists, Inc., Nashville
Texas Liver Institute, San Antonio
Liver Institute of Virginia, Richmond
Swedish Medical Center, Seattle
Auckland Clinical Studies, Auckland
Christchurch Clinical Studies Trust, Christchurch
Fundacion de Investigacion de Diego, San Juan
Lead Sponsor
Gilead Sciences
INDUSTRY